Cargando…

Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis

BACKGROUND: Desmoid tumours/aggressive fibromatosis (DT/AF) are infrequent soft-tissue neoplasms. They usually behave as indolent diseases. However, they may grow locally infiltrating or compressing adjacent structures. The role of local treatment is limited and only a few drugs have shown activity....

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Liberal, Juan, Benson, Charlotte, McCarty, Heather, Thway, Khin, Messiou, Christina, Judson, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176486/
https://www.ncbi.nlm.nih.gov/pubmed/24279994
http://dx.doi.org/10.1186/2045-3329-3-13
_version_ 1782336641735589888
author Martin-Liberal, Juan
Benson, Charlotte
McCarty, Heather
Thway, Khin
Messiou, Christina
Judson, Ian
author_facet Martin-Liberal, Juan
Benson, Charlotte
McCarty, Heather
Thway, Khin
Messiou, Christina
Judson, Ian
author_sort Martin-Liberal, Juan
collection PubMed
description BACKGROUND: Desmoid tumours/aggressive fibromatosis (DT/AF) are infrequent soft-tissue neoplasms. They usually behave as indolent diseases. However, they may grow locally infiltrating or compressing adjacent structures. The role of local treatment is limited and only a few drugs have shown activity. CASES PRESENTATION: We report the outcome of two patients affected by progressive DT/AF treated with the angiogenesis inhibitor pazopanib in two different institutions. Both patients achieved dramatic improvement in their symptoms and radiological signs of response. The clinical benefit lasted for more than 1 year and it is still ongoing. CONCLUSIONS: Pazopanib is an active treatment in DT/AF. It is the first time this has been reported.
format Online
Article
Text
id pubmed-4176486
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41764862014-09-27 Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis Martin-Liberal, Juan Benson, Charlotte McCarty, Heather Thway, Khin Messiou, Christina Judson, Ian Clin Sarcoma Res Case Report BACKGROUND: Desmoid tumours/aggressive fibromatosis (DT/AF) are infrequent soft-tissue neoplasms. They usually behave as indolent diseases. However, they may grow locally infiltrating or compressing adjacent structures. The role of local treatment is limited and only a few drugs have shown activity. CASES PRESENTATION: We report the outcome of two patients affected by progressive DT/AF treated with the angiogenesis inhibitor pazopanib in two different institutions. Both patients achieved dramatic improvement in their symptoms and radiological signs of response. The clinical benefit lasted for more than 1 year and it is still ongoing. CONCLUSIONS: Pazopanib is an active treatment in DT/AF. It is the first time this has been reported. BioMed Central 2013-11-26 /pmc/articles/PMC4176486/ /pubmed/24279994 http://dx.doi.org/10.1186/2045-3329-3-13 Text en Copyright © 2013 Martin-Liberal et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Martin-Liberal, Juan
Benson, Charlotte
McCarty, Heather
Thway, Khin
Messiou, Christina
Judson, Ian
Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
title Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
title_full Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
title_fullStr Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
title_full_unstemmed Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
title_short Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
title_sort pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176486/
https://www.ncbi.nlm.nih.gov/pubmed/24279994
http://dx.doi.org/10.1186/2045-3329-3-13
work_keys_str_mv AT martinliberaljuan pazopanibisanactivetreatmentindesmoidtumouraggressivefibromatosis
AT bensoncharlotte pazopanibisanactivetreatmentindesmoidtumouraggressivefibromatosis
AT mccartyheather pazopanibisanactivetreatmentindesmoidtumouraggressivefibromatosis
AT thwaykhin pazopanibisanactivetreatmentindesmoidtumouraggressivefibromatosis
AT messiouchristina pazopanibisanactivetreatmentindesmoidtumouraggressivefibromatosis
AT judsonian pazopanibisanactivetreatmentindesmoidtumouraggressivefibromatosis